50
Participants
Start Date
March 29, 2021
Primary Completion Date
February 16, 2024
Study Completion Date
January 19, 2025
tusamitamab ravtansine
"Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion"
Gemcitabine
"Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion"
Investigational Site Number : 1580002, Tainan City
Investigational Site Number : 0320003, Capital Federal
Investigational Site Number : 3480003, Budapest
Investigational Site Number : 0320002, Rosario
Investigational Site Number : 4100003, Goyang-si
Investigational Site Number : 1580003, Taipei
Investigational Site Number : 7240003, Madrid
Investigational Site Number : 7240002, Majadahonda
AdventHealth Orlando Site Number : 8400001, Orlando
Investigational Site Number : 7920001, Istanbul
Investigational Site Number : 1580001, Taichung
University of Wisconsin Site Number : 8400004, Madison
Investigational Site Number : 6430001, Moscow
Investigational Site Number : 6430004, Pushkin, Saint- Petersburg
Investigational Site Number : 6430002, Saint Petersburg
Investigational Site Number : 1520002, Temuco
Investigational Site Number : 1520003, Santiago
Investigational Site Number : 1520001, Santiago
Massachusetts General Hospital Site Number : 8400002, Boston
Investigational Site Number : 0320001, Pergamino
Investigational Site Number : 5280002, Amsterdam
Investigational Site Number : 5280001, Rotterdam
Investigational Site Number : 5280003, Utrecht
Investigational Site Number : 4100001, Seoul
Investigational Site Number : 4100002, Seoul
Investigational Site Number : 7240001, Barcelona
Investigational Site Number : 7920003, Adana
Investigational Site Number : 7920004, Ankara
Investigational Site Number : 7920002, Izmir
Lead Sponsor
Sanofi
INDUSTRY